iRhythm Holdings, Inc. (IRTC)

iRhythm Holdings, Inc. stock has experienced significant positive movement over the past six months, climbing by 39.1% and outperforming the S&P 500 by 27.6%. Over the past year, the share price increased by 35.19%. In January 2026, iRhythm Technologies raised its full-year 2025 revenue guidance and issued new 2026 revenue guidance of approximately $870 million to $880 million, implying 17% to 18% year-over-year growth, which was attributed to strong demand for its cardiac monitoring services and devices. Despite the positive stock performance, there has been significant insider selling activity over the past three months.

iRhythm Holdings, Inc. anticipates a strong fourth quarter, which aligns with normal seasonality for its products and services.

iRhythm Holdings, Inc. is a digital healthcare company specializing in device-based technology for ambulatory cardiac monitoring services. The company provides solutions for detecting, predicting, and preventing cardiac diseases, particularly arrhythmias, through its Zio ambulatory cardiac monitoring services. The Zio platform includes the Zio Monitor System, Zio XT System, and Zio AT System, which are prescription-only remote ECG monitoring systems that record the heart's electrical signals for up to 14 days. iRhythm combines wearable biosensors and cloud-based data analytics with proprietary algorithms to distill millions of heartbeats into clinically actionable information.

Headquartered in San Francisco, California, iRhythm Holdings, Inc. has expanded its international presence with operations in Austria, the Netherlands, Spain, and Switzerland. The Zio 14-day ECG monitoring system has also received regulatory approval in Japan.

iRhythm Holdings, Inc. has demonstrated a commitment to quality and sustainability, as highlighted in its Corporate Sustainability Report released in April 2025. The company completed a Scope 3 emissions inventory, achieved 89.5% landfill waste diversion, obtained ISO 14001:2015 certification, and was recognized in Newsweek's America's Greenest Companies 2025. The company also focused on technological innovations, enhancing quality systems, improving Electronic Health Record (EHR) integration, launching innovative products, securing strategic licensing agreements, and establishing an AI Governance Steering Committee. A collaboration with Epic was announced in February 2024 to streamline access to Zio services through EHR integration. 99% of physicians agree with the comprehensive end-of-wear report provided for iRhythm's Zio products.

iRhythm Holdings, Inc. has a substantial institutional ownership base, with 578 institutional owners and shareholders holding a total of 43,411,922 shares. Major institutional owners include Vanguard Group Inc., BlackRock, Inc., Artisan Partners Limited Partnership, Sands Capital Management, Llc, Capital Research Global Investors, VTSMX - Vanguard Total Stock Market Index Fund Investor Shares, State Street Corp, SMCWX - SMALLCAP WORLD FUND INC Class A, Geode Capital Management, Llc, and IWM - iShares Russell 2000 ETF. Individual insiders hold approximately 0.885% of the company's shares.